BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Huatangning (Dorzagliatin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Huatangning (Dorzagliatin)\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06976658-329@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Huatangning (Dorzagliatin): Phase 2 readout est. (NCT06976658)
DESCRIPTION:Huatangning (Dorzagliatin)\, phase 2.\nStudy: Glucokinase Activ
 ator in Monogenic Diabetes\nEstimated primary completion: 31 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dorzagliatin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06976658
URL:https://assetmemo.bio/drug/dorzagliatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06995651-329@assetmemo.bio
DTSTAMP:20261121T005707Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Huatangning (Dorzagliatin): Phase 1 readout est. (NCT06995651)
DESCRIPTION:Huatangning (Dorzagliatin)\, phase 1.\nStudy: Dorzagliatin in P
 ancreatic Insufficient Cystic Fibrosis\nEstimated primary completion: July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dorzagliatin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06995
 651
URL:https://assetmemo.bio/drug/dorzagliatin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
